Baxalta

Roche scores—again—in hemophilia drug patent case against Takeda
Fierce Pharma
Thu, 09/21/23 - 11:47 am
Roche
Takeda
patents
legal
Genentech
Baxalta
hemophilia
Takeda's Baxalta settles with Bayer over $173M hemophilia patent infringement verdict
Fierce Pharma
Wed, 05/19/21 - 11:05 pm
Baxalta
Takeda
hemophilia
patents
Bayer
Adynovate
Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement
BioSpace
Wed, 02/6/19 - 11:17 am
Takeda
clinical trials
Adynovate
Baxalta
Bayer
patents
Analyzing the orphan drugs market ($127bn)
GoinPharma
Fri, 03/2/18 - 09:48 am
orphan drugs
Shire
Baxalta
Sanofi
Bioverativ
M&A
Why big pharma companies always create new spinoffs
GoinPharma
Sun, 01/28/18 - 10:06 am
spinoffs
Sanofi
Celgene
Biogen
AbbVie
Abbott Labs
Baxalta
Shire
Shire defends record as UBS cuts price target on staff satisfaction reviews
Reuters
Wed, 08/30/17 - 11:43 pm
Shire
employees
Baxalta
Shire conservative as it navigates Baxalta integration
BioPharma Dive
Wed, 05/3/17 - 02:18 pm
Shire Pharmaceuticals
Baxalta
M&A
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
Fierce Pharma
Mon, 04/10/17 - 10:19 am
M&A
Stada
Shire
Baxalta
JNJ
Actelion
Mylan Labs
Pfizer
Takeda
Ariad Pharmaceuticals
Medivation
Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO
TheStreet.com
Mon, 03/27/17 - 11:03 am
Alexion Pharma
Pharma CEOs
Ludwig Hantson
Baxalta
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Endpoints
Wed, 02/22/17 - 11:43 am
M&A
Shire
Baxalta
Pfizer
Medivation
Mylan
Meda
AbbVie
Stemcentrx
Anacor
Baxalta pushes Shire to record revenues
BioPharma Dive
Thu, 02/16/17 - 03:18 pm
Shire
Baxalta
earnings
Shire's new Baxalta hemophilia meds drop the ball in first combined quarter
Fierce Pharma
Wed, 11/2/16 - 09:56 am
Shire
Baxalta
hemophilia
earnings
Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Endpoints
Tue, 10/25/16 - 09:54 am
Shire
myelofibrosis
CTI BioPharma
Baxalta
M&A
pacritinib
AbbVie Is Under Duress With Fierce Competition
Seeking Alpha
Thu, 10/20/16 - 09:20 am
AbbVie
Humira
biosimilars
Amgen
Baxalta
Shire
Shire wants out of that $172M Baxalta deal with CTI Bio
Endpoints
Mon, 09/19/16 - 06:03 pm
Shire
Baxalta
CTI BioPharma
M&A
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
Fierce Biotech
Wed, 08/3/16 - 09:39 am
Shire
Baxalta
hemophilia B
gene therapy
BAX 335
Spark Therapeutics
uniQure
Shire upgrades Baxalta cost savings after Q2 earnings beat
Yahoo/Reuters
Tue, 08/2/16 - 09:03 am
Shire
Baxalta
earnings
Shire bags a quick thumbs up for its newly won cancer drug pipeline
Endpoints
Mon, 07/25/16 - 11:15 am
Shire
Baxalta
M&A
Onivyde
Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta
TheStreet.com
Thu, 07/14/16 - 07:21 pm
Shire
ADHD
Baxalta
Brexit
M&A
Vyvanse
Shire completes Baxalta acquisition
Bizjournals.com
Fri, 06/3/16 - 09:58 am
Shire
Baxalta
M&A

Pages